EuroPCR Highlights: TAVI Set to Continue Rampant Growth
With innovation as the theme of this year's EuroPCR meeting, emerging technology sessions and innovation presentations sparked lively discussions. While drug-eluting stents remained a key interest area, transcatheter aortic heart valve implantation sessions drew the largest crowds.
You may also be interested in...
In the interventional cardiology community, 2010 could certainly be considered a breakthrough year for percutaneous heart valve devices. At two major US cardiology conferences: the American College of Cardiology in the spring, and most recently, the Transcatheter Cardiovascular Therapeutics symposium, held in September, impressive results from randomized trials of transcatheter heart valve replacement/repair devices set the venues abuzz and had physicians speculating about possible near-term paradigm shifts in the way heart valve disease will be treated. The big questions now are how long it will take before these devices reach the US market, and exactly how many US patients are likely to be implanted once they are available.
Brief summaries of recent medtech market and industry developments. This month we cover Covidien's acquisition of ev3, J&J's moves in the endovascular market, DePuy's launch of new products in hip revision, and FDA regulation of consumer genomics.
Every year for just about the past decade, drug-eluting stents dominated the agenda at the Paris Course on Revascularization and just about any meeting where interventional cardiologists gathered to hear the latest in technology and practice innovation. But without question, the star of this year’s PCR was percutaneous heart valves and, in particular the revolution in transaortic valve replacement that has been ushered in by Edwards Lifesciences., which acquired Percutaneous Valve Technologies several years ago, and Medtronic., as a result of its more recent CoreValve acquisition.